Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

JCO Early Release, published online ahead of print Nov 9 2009
Journal of Clinical Oncology, 10.1200/JCO.2009.23.7503

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Google Scholar
Right arrow Articles by Makishima, H.
Right arrow Articles by Maciejewski, J. P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Makishima, H.
Right arrow Articles by Maciejewski, J. P.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Received April 23, 2009
Accepted August 6, 2009

Mutations of E3 Ubiquitin Ligase Cbl Family Members Constitute a Novel Common Pathogenic Lesion in Myeloid Malignancies

Hideki Makishima, Heather Cazzolli, Hadrian Szpurka, Andrew Dunbar, Ramon Tiu, Jungwon Huh, Hideki Muramatsu, Christine O'Keefe, Eric Hsi, Ronald L. Paquette, Seiji Kojima, Alan F. List, Mikkael A. Sekeres, Michael A. McDevitt, and Jaroslaw P. Maciejewski*

From the Departmenst of Translational Hematology and Oncology Research and Hematologic Oncology and Blood Disorders, Taussig Cancer Institute; Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH; Department of Laboratory Medicine, Ewha Woman's University, School of Medicine, Seoul, South Korea; University of California Los Angeles, Los Angeles, CA; H. Lee Moffitt Cancer Center, Tampa, FL; Division of Hematology and Hematological Malignancy, Department of Medicine and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD; and the Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.

* To whom correspondence should be addressed. E-mail: maciejj{at}ccf.org

Purpose: Acquired somatic uniparental disomy (UPD) is commonly observed in myelodysplastic syndromes (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), or secondary acute myelogenous leukemia (sAML) and may point toward genes harboring mutations. Recurrent UPD11q led to identification of homozygous mutations in c-Cbl, an E3 ubiquitin ligase involved in attenuation of proliferative signals transduced by activated receptor tyrosine kinases. We examined the role and frequency of Cbl gene family mutations in MPN and related conditions.

Methods: We applied high-density SNP-A karyotyping to identify loss of heterozygosity of 11q in 442 patients with MDS, MDS/MPN, MPN, sAML evolved from these conditions, and primary AML. We sequenced c-Cbl, Cbl-b, and Cbl-c in patients with or without corresponding UPD or deletions and correlated mutational status with clinical features and outcomes.

Results: We identified c-Cbl mutations in 5% and 9% of patients with chronic myelomonocytic leukemia (CMML) and sAML, and also in CML blast crisis and juvenile myelomonocytic leukemia (JMML). Most mutations were homozygous and affected c-Cbl; mutations in Cbl-b were also found in patients with similar clinical features. Patients with Cbl family mutations showed poor prognosis, with a median survival of 5 months. Pathomorphologic features included monocytosis, monocytoid blasts, aberrant expression of phosphoSTAT5, and c-kit overexpression. Serial studies showed acquisition of c-Cbl mutations during malignant evolution.

Conclusion: Mutations in the Cbl family RING finger domain or linker sequence constitute important pathogenic lesions associated with not only preleukemic CMML, JMML, and other MPN, but also progression to AML, suggesting that impairment of degradation of activated tyrosine kinases constitutes an important cancer mechanism.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2009 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online